Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma

Modern Pathology

Volumn 20, Issue 2, 2007, Pages 215-220

  Kato, Yasufumi ^a   Tsuta, Koji ^a   Seki, Kunihiko ^a   Maeshima, Akiko Miyagi ^b   Watanabe, Shunichi ^a   Suzuki, Kenji ^a   Asamura, Hisao ^a   Tsuchiya, Ryosuke ^a   Matsuno, Yoshihiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Glut 1; Immunohistochemistry; Lung carcinoma; Malignant pleural mesothelioma; Reactive methothelium

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE TRANSPORTER 1;

ARTICLE; CANCER DIAGNOSIS; CELL MEMBRANE; CYTOPLASM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MALIGNANT MESOTHELIOMA; MESOTHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STAINING;

ADENOCARCINOMA; CELL MEMBRANE; DIAGNOSIS, DIFFERENTIAL; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; PLEURISY; TUMOR MARKERS, BIOLOGICAL;

EID: 33947265299     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800732     Document Type: Article

References (36)

1. Allen TC, Cagle PT, Churg AM, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000;24:1183-2000.
2. Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology 1997;30:403-418.
3. Cury PM, Butcher DN, Corrin B, et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 1999;189:251-257.
4. Salas A, Fernandez-Banares F, Casalots J, et al. Utility of epithelial membrane antigen and p53 in the differential diagnosis of benign reactive processes from malignancy in pleural biopsy specimens. Virchows Arch 1999;435:286.
5. Roberts F, Harper CM, Downie I, et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. Am J Clin Pathol 2001;116:253-262.
6. Kafiri G, Thomas DM, Shepherd NA, et al. p53 expression is common in malignant mesothelioma. Histopathology 1992;21:331-334.
7. Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pathol 1992;168:377-381.
8. Ramael M, Buysse C, van den Bossche J, et al. Immunoreactivity for the b chain of the platelet-derived growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992;167:1-4.
9. Ramael M, Lemmens G, Eerdekens C, et al. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 1992;168:371-375.
10. Cagle PT, Brown RW, Lebovitz RM. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol 1994;25:443-448.
11. Esposito V, Baldi A, De Luca A, et al. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations. Anticancer Res 1997;17:733-736.
12. Ramael M, van den Bossche J, Buysse C, et al. Immunoreactivity for P-170 glycoprotein in malignant and in non-neoplastic mesothelium of the pleura arising the murine monoclonal antibody JSB-1. J Pathol 1992;167:5-8.
13. Segers K, Kumar-Singh S, Weyler J, et al. Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch 1994;242:631-634.
14. Olson AL, Pessin JE. Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr 1996;16:235-256.
15. Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res 1996;56:1164-1167.
16. Godoy A, Ulloa V, Rodriguez F, et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006;207:614-627.
17. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993;72:2979-2985.
18. Mellanen P, Minn H, Grenman R, et al. Expression of glucose transporters in head-and-neck tumors. Int J Cancer 1994;56:622-629.
19. Nagase Y, Takata K, Moriyama N, et al. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 1995;153:798-801.
20. Younes M, Brown RW, Stephenson M, et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-1051.
21. Ito T, Noguchi Y, Satoh S, et al. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 1998;11:437-443.
22. Brown RS, Leung JY, Kison PV, et al. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999;40:556-565.
23. Chang S, Lee S, Lee C, et al. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology 2000;55:448-452.
24. Mamede M, Higashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005;7:369-379.
25. Weiner MF, Miranda RN, Bardales RH, et al. Diagnostic value of GLUT-1 immunoreactivity to distinguish benign from malignant cystic squamous lesions of the head and neck in fine-needle aspiration biopsy material. Diagn Cytopathol 2004;31:294-299.
26. Chandan VS, Faquin WC, Wilbur DC, et al. The utility of GLUT-1 immunolocalization in cell blocks: an adjunct to the fine needle aspiration diagnosis of cystic squamous lesions of the head and neck. Cancer 2006;108:124-128.
27. Burstein DE, Reder I, Weiser K, et al. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions. Mod Pathol 1998;11:392-396.
28. Zimmerman RL, Goonewardene S, Fogt F. Glucose transporter Glut-1 is of limited value for detecting breast carcinoma in serous effusions. Mod Pathol 2001;14:748-751.
29. Afify A, Zhou H, Howell L, et al. Diagnostic utility of Glut-1 expression in the cytologic evaluation of serous fluids. Acta Cytol 2005;49:621-626.
30. Churg A, Roggli V, Galateau-Salle F, et al. Mesothelioma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds). Pathology and Genetics: Tumors of the Lung, Pleura, Thymus and Heart. IARC: Lyon, France, 2004, pp 128-136.
31. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005;129:1407-1414.
32. Merrall NW, Plevin R, Gould GW. Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 1993;5:667-675.
33. Mueckler M. Facilitative glucose transporters. Eur J Biochem 1994;219:713-725.
34. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-1632.
35. Newsholme EA, Board M. Application of metabolic-control logic to fuel utilization and its significance in tumor cells. Adv Enzyme Regul 1991;31:225-246.
36. Carretta A, Landoni C, Melloni G, et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases-a pilot study. Eur J Cardiothorac Surg 2000;17:377-383.